Trial Profile

AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 17 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Catequentinib (Primary) ; Paclitaxel (Primary) ; Penpulimab (Primary)
Indications Advanced breast cancer; Triple negative breast cancer
Focus Therapeutic Use
Sponsors Chia Tai Tianqing Pharmaceutical Group

Most Recent Events

09 Dec 2023 Status changed from not yet recruiting to recruiting, as per presented at the 46th Annual San Antonio Breast Cancer Symposium
10 Dec 2022 Trial design presented at the 45th Annual San Antonio Breast Cancer Symposium
11 Jul 2022 Planned initiation date changed from 1 May 2022 to 1 Jul 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com